newsfilter
← Latest News
GlobeNewswire·

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YDES
  • YD Bio Limited reported net revenue of $846,501 for the six months ended June 30, 2026, representing a 315% increase compared to $204,007 in the same period in 2025.
  • The company achieved a net income of $6.7 million for the period, a turnaround from a net loss of $1.9 million in 2025, primarily driven by a $9.8 million non-cash gain from the change in fair value of warrant liabilities.
  • Net revenue growth was largely attributed to a $327,060 single order for Fetroja for Injection from a top client, which accounted for 39% of total revenue.
  • Cost of revenue rose 328% to $578,271 due to lower margins on large sales orders, while gross profit increased 290% to $268,230.
  • Total operating expenses increased by 73% to $3.5 million, driven by $0.5 million in higher staff costs, $0.4 million in marketing expenses, $0.3 million in R&D expenses for licensed patents, and $0.1 million in professional fees.
  • Excluding non-cash warrant liability adjustments, the unadjusted operational net loss increased by 64% to $3.1 million.
  • Cash and cash equivalents decreased by $3.3 million to $2.66 million as of June 30, 2026, due to payments for R&D, staff costs, product purchases, professional fees, and office space prepayments.
  • YD Bio launched an online EG Telehealth Platform in March 2026 to support blood-based multi-cancer tests via EG BioMed.
  • The company expanded its multi-state laboratory network to 47 U.S. states plus territories, including Washington D.C., Guam, the U.S. Virgin Islands, and American Samoa.
  • A six-month Canadian pilot with Numia Health was launched to evaluate cross-border, blood-based cancer detection using OkaiDx tests.
  • YD Bio announced a non-binding Memorandum of Understanding to merge with EG BioMed on January 6, 2026, to enhance DNA methylation diagnostics.
  • The company entered a binding Letter of Intent to acquire 100% of Safe Save Medical Cell Sciences & Technology Co., Ltd. for approximately $26.87 million.
  • YD Bio established a Master Strategic Alliance with YC Biotech Co., Ltd. to act as its exclusive U.S. agent, generating $66,642 in revenue for the period.
  • The company completed key milestones for licensed LSC-derived exosome technologies, including purification process development and animal study evaluations.
  • YD Bio paid $2.82 million under a patent agreement with 3D Global for cell source development, stability examination, and exosome raw material development.
  • A physician-partnership model was launched in Taiwan on August 11, 2026, involving collaborations with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute.
  • Supplier concentration remained high with two suppliers accounting for approximately 42.9% and 19.2% of purchases during the six months ended June 30, 2026.